Posters - NCDEU: An Annual Meeting Sponsored by ASCP

Posters
57. Incidence and Time Course of Extrapyramidal Symptoms (EPS):
Oral vs. Long-Acting Injectable (LAI) Paliperidone
David Hough, Janssen Research & Development
Srihari Gopal, Yanning Liu, Larry Alphs, Adam Savitz, Isaac Nuamah
58. Within-Drug Benefit/Risk of Olanzapine LAI at 1 and 2 Years of
Treatment
Michael Shepherd, Eli Lilly Canada, Inc.
Holland Detke, John Lauriello, Susan Watson, David McDonnell, John
Landry
59. Examining Methods for Computing “Clinical Response” in
Placebo Controlled Trials of Antipsychotics in the NEWMEDS
Repository
Jonathan Rabinowitz, Bar Ilan University
Nomi Werbeloff, François Menard, Judith Jaeger, Bruce Kinon, Virginia
Stauffer, Francine Mandel, Shitij Kapur
60. A Chemical Biology Approach to Identify Disease Signatures in
Schizophrenia and Bipolar Disorder using iPSC-derived Neuronal
Cells: Implications for High-throughput Screening
Rakesh Karmacharya, Massachusetts General Hospital, McLean
Hospital
Steven Sheridan, Sabine Bavamian, Jennifer Wang, Kraig Theriault,
Elizabeth O’Brien, Sigrun Gustafdottir, Katherine Madden, Donna
McPhie, Roy Perlis, Dost Ongur, Alykhan Shamji, Anne Carpenter,
Bruce Cohen, Stuart Schreiber, Stephen Haggarty
61. PNB02: A Beneficial Treatment for Insufficient Response with
Single Agent Treatment in Schizophrenia?
Erik Buntinx, PharmaNeuroBoost NV
Ludo Haazen, Didier de Chaffoy, Philip Harvey
62. Lurasidone for the Acute Treatment of Adults with Schizophrenia:
What is the Number Needed to Treat, Number Needed to Harm,
and Likelihood to be Helped or Harmed?
Leslie Citrome, Nathan S. Kline Institute for Psychiatric Research
63. Bleak House: A Study of Schizophrenia in the Era of
Deinstitutionalization
Reuven Ferziger, Janssen Scientific Affairs, LLC
Lian Mao, Cynthia Bossie, Larry Alphs
= New Investigator Q Pharmaceutical Pipeline
79